1. Home
  2. RRR vs ADPT Comparison

RRR vs ADPT Comparison

Compare RRR & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Red Rock Resorts Inc.

RRR

Red Rock Resorts Inc.

N/A

Current Price

$54.68

Market Cap

3.6B

ML Signal

N/A

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

N/A

Current Price

$24.34

Market Cap

4.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RRR
ADPT
Founded
1976
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
4.1B
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
RRR
ADPT
Price
$54.68
$24.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
9
Target Price
$69.69
$17.78
AVG Volume (30 Days)
723.0K
1.7M
Earning Date
04-29-2026
05-05-2026
Dividend Yield
3.64%
N/A
EPS Growth
23.32
63.89
EPS
1.40
N/A
Revenue
$2,011,483,000.00
$276,976,000.00
Revenue This Year
$3.41
$3.98
Revenue Next Year
$4.62
$22.72
P/E Ratio
$40.09
N/A
Revenue Growth
3.74
54.77
52 Week Low
$50.52
$12.00
52 Week High
$68.99
$26.87

Technical Indicators

Market Signals
Indicator
RRR
ADPT
Relative Strength Index (RSI) 27.78 49.67
Support Level $51.19 $23.92
Resistance Level $59.34 $26.51
Average True Range (ATR) 1.56 1.02
MACD -0.34 -0.30
Stochastic Oscillator 5.23 24.46

Price Performance

Historical Comparison
RRR
ADPT

About RRR Red Rock Resorts Inc.

Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos, followed by Food and Beverages, Rooms and others.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: